GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Ltd on Tuesday reported a 9.45 per cent rise in consolidated net profit at Rs 164.56 crore in the third quarter ended December 31, 2022. The company had posted a consolidated net profit of Rs 150.35 crore in the same quarter last fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 802.3 crore as against Rs 815.92 crore in the year-ago period, it added. Total expenses were lower at Rs 590.1 crore compared to Rs 636.56 crore in the corresponding quarter last fiscal. "General medicines portfolio grew by 10 per cent led by anti-infectives and dermatology therapies...Vaccine sales were down for the quarter in a declining self-pay vaccines market. However, we continue to gain market share for key vaccine brands," GSK Pharma Managing Director Bhushan Akshikar said. During the quarter, he said, the National List of Essential Medicines (NLEM), 2022

/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organisation (CRO-CDMO), today announced the joining of Stephen Hermitage (Steve) as Vice President, CMC. In this role Steve will join the global R&D leadership team at Sai Life Sciences, where he will add further deep scientific, process development and drug development experience to the R&D organisation. Making the announcement, Sauri Gudlavalleti, Chief Operating Officer said, "Over the past few years, our team has established a formidable reputation for itself as a high-quality scientific unit that can solve complex chemistry challenges. I am delighted to welcome Steve, a pharma industry veteran, onboard at Sai Life Sciences. His addition to our global delivery team further strengthens our ongoing efforts to build strong client partnerships and exceed client expectations by raising the bar on innovation, speed, and efficiency. Steve joins Sai Life Sciences from GlaxoSmithKline (GSK)

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased 3 per cent to Rs 193 crore in the second quarter ended September. The drug maker had reported a net profit from continuing operations at Rs 187 crore in the July-September period of the previous fiscal. However, revenue from operations declined to Rs 906 crore in the second quarter of the current fiscal compared to Rs 916 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK India has delivered another quarter of strong performance in general medicines and specialty business, gaining market share. We hope to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth," GlaxoSmithKline Pharmaceuticals Managing Director Sridhar Venkatesh said. Vaccines business was impacted due to low vaccination rates as the overall market for the self-pay segment in which the company operates continues to decline, he ...

Stocks to Watch: Investors Gray Birch, Plenty PE & Multiples PE may sell up to 7.74 per cent stake in PVR today in a price range of Rs 1,852-1,929/share, as per reports

Serum India's product made in collaboration with state-run biotechnology department, expected to bring down prices

Drug manufacturers GlaxoSmithKline on Monday said its consolidated net profit increased to Rs 116 crore in the first quarter. Shares of the company closed at Rs 1,726.20 on BSE, said reports

Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said in a regulatory filing

The results underscore a comeback for GSK in the race to help fight the Covid-19 pandemic after it failed to bring a vaccine to the market so far

The management expects this positive momentum to continue through the second half of the year driving the company towards the better end of a meaningful performance improvement.

Vaccines are not consumer products made by pharmaceutical industry: they are infrastructure.

Near-term gains may be limited given restrictions which will impact anti-infectives portfolio

Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise US prices on more than 300 drugs in the United States on Jan 1

Drug firm GlaxoSmithKline Pharmaceuticals on Wednesday reported nearly 85 per cent decline in its consolidated net profit to Rs 76.47 crore for the quarter ended in September. The company had posted a net profit of Rs 502.75 crore for the corresponding period of the previous fiscal, it said in a BSE filing. Consolidated revenue from operations of the company stood at Rs 879.32 crore for the quarter under consideration. It was Rs 882.02 crore for the same period a year ago, it added. The company has recognised a financial impact of Rs 64.13 crore for the latest September quarter mainly to reflect the estimated realisable value of the assets, associated costs and impacts of reversal of provision on account of Zinetac recall, the filing said. The company had recognised an exceptional item of Rs 401.14 crore for the quarter ended September 30, 2019, it added. "GSK continues to demonstrate resilience in these times, as we focus our efforts on the safety of our employees while ensuring

Sanofi and GSK said they had reached an agreement with Britain to supply it with up to 60 million doses of a potential Covid-19 vaccine, and that discussions with other governments were ongoing

Many drugmakers are racing to come up with a safe and effective vaccine that can be produced at large scale

The company had posted a net profit of Rs 146.81 crore for the same period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.

GSK leads the charge with staggered return-to-work, others plans yoga sessions and health care webinars for salesperson's family

Over 133 million shares, or 5.7% of the paid-up capital, are being offered for Rs 1,850-1,950 to investors through a special block window

The company reported a consolidated net loss of Rs 661 crore for the quarter, mainly on account of financial impact related to the voluntary recall of Zinetac

STEER which was founded in 1993 by Padmanabhan has 5 global offices and 10 satellite offices, serving over 39 countries. It employs over 500 engineers, scientists and technicians across the globe